Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProCAID
ISRCTN69139368Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jan 2013
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of capivasertib in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Determination of a suitable dose of AZD5363 and Progression-free survival from start of study treatment. Started Jan 2013; status: completed.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ISRCTN69139368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN69139368.